Helen Louise Collins - Apr 11, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Apr 11, 2024
Transactions value $
-$451,878
Form type
4
Date filed
4/15/2024, 07:02 PM
Previous filing
Feb 15, 2024
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $49.6K +20K $2.48 20K Apr 11, 2024 Direct F1
transaction ELVN Common Stock Sale -$501K -20K -100% $25.07 0 Apr 11, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -20K -6.97% $0.00 267K Apr 11, 2024 Common Stock 20K $2.48 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $25.00 to $25.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.